Show simple item record

Chemotherapy for advanced non-small cell lung cancer.

dc.contributor.authorThatcher, Nick
dc.date.accessioned2009-10-13T08:23:01Z
dc.date.available2009-10-13T08:23:01Z
dc.date.issued2001-12
dc.identifier.citationChemotherapy for advanced non-small cell lung cancer. 2001, 34 Suppl 2:S171-5 Lung Canceren
dc.identifier.issn0169-5002
dc.identifier.pmid11720761
dc.identifier.urihttp://hdl.handle.net/10541/84115
dc.description.abstractChemotherapy for advanced NSCLC in good performance status has survival benefit, reduces tumour symptoms and can improve quality of life. Future challenges include defining the optimal chemotherapy and incorporating the newer agents to improve patients' outcome. In particular treatment of the elderly and patients with poorer performance status need to be developed with more attention being paid to relief of symptoms and minimising treatment toxicity.
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshHealth Status
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshPrognosis
dc.subject.meshQuality of Life
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshSurvival Analysis
dc.titleChemotherapy for advanced non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentChristie and Wythenshawe Hospitals, Wilmslow Road, M20 4BX, Manchester, UK. linda.aschcroft@christie-tr.nwest.nhs.uken
dc.identifier.journalLung Canceren
html.description.abstractChemotherapy for advanced NSCLC in good performance status has survival benefit, reduces tumour symptoms and can improve quality of life. Future challenges include defining the optimal chemotherapy and incorporating the newer agents to improve patients' outcome. In particular treatment of the elderly and patients with poorer performance status need to be developed with more attention being paid to relief of symptoms and minimising treatment toxicity.


This item appears in the following Collection(s)

Show simple item record